Celltrion

Celltrion is a global biopharmaceutical company headquartered in Incheon, South Korea, and founded in 2002. It operates an integrated, one-stop model covering research and development, clinical trials, regulatory affairs, manufacturing and distribution. Its production facilities are certified to cGMP standards by the US Food and Drug Administration and the European Medicines Agency, and its products are approved in approximately 100 countries, including the regulated markets of the United States and Europe.

The company develops and manufactures monoclonal antibody biosimilars. It launched the world's first monoclonal antibody biosimilar, and it is Korea's largest manufacturer and exporter of biosimilars. Its therapeutic areas span immunology, oncology, hematology, ophthalmology and endocrinology.

Celltrion reports annual production capacity of 250,000 litres and a production success rate of over 99%. It reinvests approximately 20% of revenue in research and development each year. The company states that its work is directed at making advanced treatments more accessible to patients worldwide.